Frailty and Metabolic Health in Transplant Candidates

Nov 07 2026
Convention Center: Bluebird Ballroom 3ABC
5:00 PM - 6:30 PM
Captured/recorded session Recorded
CE Credits CE Credits

World Class Speakers

Stephanie Z Zhang

Abstract Presenter
SZ

Sri Harsha Boppana

Abstract Presenter
Sri Harsha Boppana, MBBS, MD.

Kacey Berry

Abstract Presenter
Kacey Berry, MD, MAS

Joseph R Gunderson

Abstract Presenter
JG

Kavish Patidar

Abstract Presenter
Kavish Patidar, END

Babak J Orandi

Abstract Presenter
BO

David S. Goldberg

Moderator
David S. Goldberg, MD, MSCE

Ryutaro P Hirose

Moderator
Ryutaro P Hirose, MD

Description

This session explores the interplay between frailty, metabolic health, and long-term outcomes across the liver transplant continuum. Presentations characterize frailty and cardiovascular-kidney-metabolic risk from candidacy through post-transplant recovery, and examine emerging therapeutic strategies—including GLP-1 receptor agonists—to improve survival and reduce cardiometabolic complications. Together, these studies highlight opportunities to refine risk stratification and intervene on modifiable factors that shape recipient outcomes.

Presentations

5:00 PM - 5:15 PM
Convention Center - Bluebird Ballroom 3ABC
Recorded session

Identifying an Outcome-Based Liver Frailty Index Cutoff to Define Robustness as a Target for Frailty Intervention

Stephanie Z Zhang, MSc | Abstract Presenter
5:15 PM - 5:30 PM
Convention Center - Bluebird Ballroom 3ABC
Recorded session

Metabolic Frailty Phenotyping and machine learning for Predicting Graft Failure After Liver Transplantation for MASH

Sri Harsha Boppana, MBBS, MD. | Abstract Presenter
5:30 PM - 5:45 PM
Convention Center - Bluebird Ballroom 3ABC
Recorded session

Cognitive impairment is highly prevalent after liver transplantation and associated with pre-transplant frailty 

Kacey Berry, MD, MAS | Abstract Presenter
5:45 PM - 6:00 PM
Convention Center - Bluebird Ballroom 3ABC
Recorded session

Cardiovascular-Kidney-Metabolic Syndrome Stage at One Year Predicts Cardiovascular, Renal, and Transplant Outcomes After Liver Transplantation

Joseph R Gunderson, MD | Abstract Presenter
6:00 PM - 6:15 PM
Convention Center - Bluebird Ballroom 3ABC
Recorded session

GLP-1 Receptor Agonists Are Associated With Improved Survival and Cardio-Kidney Outcomes Without Increased Rejection in Liver Transplant Recipients With Diabetes: A Nationwide Target Trial Emulation

Kavish Patidar, END | Abstract Presenter
6:15 PM - 6:30 PM
Convention Center - Bluebird Ballroom 3ABC
Recorded session

Outcomes of GLP-1 Use in Liver Transplant Recipients with Diabetes and Obesity: A National Target Trial Emulation Study

Babak J Orandi, MD, PhD, MSc | Abstract Presenter

Objectives

  • Apply outcome-based frailty and metabolic phenotyping tools to identify liver transplant candidates and recipients at elevated risk for adverse outcomes.
  • Evaluate the impact of cardiovascular-kidney-metabolic syndrome on cardiovascular, renal, and graft outcomes after liver transplantation.
  • Describe the association between GLP-1 receptor agonist use and survival, cardiometabolic outcomes, and rejection risk in transplant recipients with diabetes or obesity.
  • Recognize the prevalence and clinical significance of post-transplant cognitive impairment and its link to pre-transplant frailty.

Copyright © 2026 American Association for the Study of Liver Diseases

AASLD 2026